NCT05360914 Hospital at Home for Elderly Acute Ill Patients
| NCT ID | NCT05360914 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Defactum, Central Denmark Region |
| Condition | Cystitis |
| Study Type | INTERVENTIONAL |
| Enrollment | 849 participants |
| Start Date | 2022-06-01 |
| Primary Completion | 2027-08 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 849 participants in total. It began in 2022-06-01 with a primary completion date of 2027-08.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Many elderly patients with uncomplicated treatment courses are admitted unnecessarily, which is a burden for the patient and society. Studies show that Hospital at Home (HaH) treatment is an alternative to hospitalization. The patient's risk of delirium, infection and loss of function is reduced when the patient avoids the hospital stay. HaH treatment is expected to be more cost-effective, improve patients' functional abilities and patients' satisfaction. Three municipalities, general practitioners, pre-hospital service and an emergency department (ED) in Central Denmark Region have organized the first HaH treatment model across disciplines and sectors. Specialists in the ED and the municipal acute teams provide HaH treatment for elderly acute ill patients. However, the model has not yet been evaluated. The aim of this study is to optimize the HaH treatment model for elderly acute ill patients. The objective is to increase patient satisfaction and optimize the use of resources in healthcare by avoiding unnecessary hospitalizations that impair and prolong treatment. This study is an open label randomized controlled trial (RCT) with a 1:2 allocation ratio of acute hospital admission versus HaH. During a pilot period, we tested and adapted the patient pathway of HaH to the practical reality, before we start the randomization for the RCT study. We will investigate the clinical effects and health economic consequences of HaH treatment compared with standard hospital treatment.
Eligibility Criteria
Inclusion Criteria: * The patient should be aged 65 and over * Diagnosed with a stable acute medical conditions e.g. cystitis, erysipelas, pneumonia * The patient should be living in their own home or a nursing home before entering the study * The patient should be residing in one of the three municipalities (Viborg, Skive and Silkeborg) * The patient must have been seen by the GP or the pre-hospital service in the case of disease in question * The patient should speak and understand Danish. * The patient should give informed consent to participate in the study. Exclusion Criteria: * The patient is unable to give written consent * The capacity of the municipal acut team care was fully utilised.
Contact & Investigator
Camilla Palmhøj Nielsen, Ph.D
PRINCIPAL INVESTIGATOR
Defactum, Central Denmark Region
Frequently Asked Questions
Who can join the NCT05360914 clinical trial?
This trial is open to participants of all sexes, aged 65 Years or older, studying Cystitis. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05360914 currently recruiting?
Yes, NCT05360914 is actively recruiting participants. Contact the research team at camilla.palmhoj@rm.dk for enrollment information.
Where is the NCT05360914 trial being conducted?
This trial is being conducted at Silkeborg, Denmark, Skive, Denmark, Viborg, Denmark.
Who is sponsoring the NCT05360914 clinical trial?
NCT05360914 is sponsored by Defactum, Central Denmark Region. The principal investigator is Camilla Palmhøj Nielsen, Ph.D at Defactum, Central Denmark Region. The trial plans to enroll 849 participants.